Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01164917 · ClinicalTrials.gov registry record · Phase 1
Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01164917 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 16 participants.
The verdict
NCT01164917, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, double-blind, placebo-controlled, two-period, crossover study in which approximately 20 subjects with Discoid Lupus Erythematosus will be enrolled to receive AMG 811 and placebo in one of two sequences (ie, AMG 811 followed by placebo or placebo followed by AMG 811).
Interventions
- DRUG AMG811
- DRUG AMG811 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2010-08 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01164917
The ClinicalTrials.gov registry entry for NCT01164917 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AMG811 is the first listed.
NCT01164917 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01164917 about?
NCT01164917 is a clinical study titled "Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus". This is a multi-center, randomized, double-blind, placebo-controlled, two-period, crossover study in which approximately 20 subjects with Discoid Lupus Erythematosus will be enrolled to receive AMG 811 and placebo in one of two sequences (ie, AMG 811 followed by placebo or placebo followed by AMG 81...
What is the current status of trial NCT01164917?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2010-08. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01164917?
The interventions under investigation include: AMG811 (DRUG), AMG811 Placebo (DRUG).
Who is sponsoring clinical trial NCT01164917?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.